



GSK Collaborative Working Executive Summary

Improving equitable access to National Adult Immunisation Programmes

This summary has been written by GSK with consultation and approval from the Collaborative Working Project Team.

GSK is committed to supporting the improvement of vaccination delivery in the UK, and is undertaking Collaborative Working projects that will build on work completed in the 2023 pilot conducted by GSK and Bury GP Federation.

GSK will engage with NHS organisations (ICBs/Health Boards/GP Federations/PCNs) to identify and agree on Collaborative Working projects, with a focus on areas of greatest need. This involves prioritising areas where national adult immunisation programme (excluding flu and COVID) uptake is lower than average, and deprivation levels are above average.

The project involves provision of non-clinical staff via a third-party into primary care practices to support with eligible patient search/identification and call/recall in Shingles and Pneumococcal National Immunisation Programmes. Clinical review of eligible patients for vaccination, and the administering of the vaccinations to patients will remain the responsibility of the NHS organisations.

Executive Summary documents for each project with specific NHS organisations will be published on the GSK UK website prior to commencement of Collaborative Working delivery. A Summary of Outcomes Report will also be published on the GSK website within six months of project completion.

Primary project objectives:

1. Reduce patient health inequalities and patient suffering from vaccine preventable diseases (shingles and pneumococcal disease).
2. Increase the uptake of shingles and pneumococcal vaccination in line with the NIP eligibility criteria in areas of greatest need.
3. Leave a sustained legacy of enhanced immunisation programme implementation by enhancing knowledge, capability and effective ways of working.

The project will run from June 2024 to December 2025, and will involve a balance of contributions from all parties, with the pooling of skills, experience and resources.

Intended benefits:

Patient:

- Increased protection from shingles and pneumococcal disease, likely resulting in improved health outcomes through greater uptake of vaccination.
- Reduced health inequalities and reduced patient suffering from shingles and pneumococcal disease.
- Fewer shingles and pneumococcal cases and related complications, which could lead to fewer hospitalisations and management of chronic pain.

- Improved experience of the healthcare system through engaging in improved vaccination service provision.

NHS:

- Increased uptake of shingles and pneumococcal disease vaccination in line with national guidance.
- Improved long-term capability to implement and deliver adult immunisation programmes.
- Reduced administrative burden on practice staff for implementing immunisation programmes.
- Support to implement best practice for achievement of Quality and Outcomes Framework (QOF) targets and national voluntary annual directed quality indicators.
- Reduced prevalence of shingles and pneumococcal disease resulting in reduced healthcare utilisation in both primary care and any associated complications and hospitalisations.
- Share learnings across NHS organisations to improve NIP implementation best practice, leading to increased uptake across ICBs/Federations/PCNs/practices.
- Transfer of knowledge to local practice administrative staff through training and upskilling from Primary Care Immunisation Facilitator.
- Systems/frameworks and administrative solutions implemented for effective patient recall.
- Searches left on practice system after Immunisation Administrator 'placement' for practice staff to utilise.
- Increased Item of Service (IOS) fee payments from increased delivery of shingles and pneumococcal vaccinations administered in line with national guidance.
- Increased patient satisfaction with practice provision of vaccinations.

GSK:

- Leave a legacy within NHS practices of sustained successful implementation of pneumococcal and shingles immunisation programmes.
- Demonstration of the effectiveness of Collaborative Working in driving implementation of vaccination across areas of greatest need.
- Increased uptake of the approved Shingles NIP and its approved guidelines.
- Support GSK's commitment to being ambitious for patients.